CTRI/2019/10/021504尚未招募3 期
A phase IIIB/IV randomised open-label trial to compare dolutegravir+ pharmaco-enhanced darunavir versus dolutegravir with predetermined nucleosides versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy: the D2EFT study. - D2EFT
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. HIV-1 positive by licensed diagnostic test
- •2. Aged >=18 years of age
- •3. Failed first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) + 2NRTI combination therapy according to virological criteria, defined as at least two consecutive (>=7 days apart) pVL results >500 copies/mL after a minimum period of exposure to continuous NNRTI + 2NRTI firstline therapy of 24 weeks (only the second pVL result needs to be within 45 days of randomisation)
- •4. For women of child-bearing potential, willingness to use appropriate contraception
- •5. Able to provide written informed consent
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493EUCTR2004-004061-15-ESShire Pharmaceutical Development Ltd.146
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493EUCTR2004-004061-15-IEShire Pharmaceutical Development Ltd.184
进行中（未招募）
不适用
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemiaMedDRA version: 12.0Level: LLTClassification code 10015493Term: Essential thrombocythaemiaEUCTR2004-004061-15-PLShire Pharmaceutical Development Ltd.184
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.EUCTR2004-004061-15-BEShire Pharmaceutical Development Ltd.146
进行中（未招募）
1 期
A study to compare the safety and effectiveness of anagrelide and hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemiaMedDRA version: 14.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-004061-15-BGShire Pharmaceutical Development Ltd.184